Understanding how bladder cancer resists immune therapy
Dissecting innate immune mechanisms of resistance to checkpoint blockade therapy in bladder cancer
This study is looking at why some bladder cancer patients don’t respond well to a new immune therapy, and by examining samples from their tumors, blood, and urine, researchers hope to find clues that could lead to better treatments for everyone.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10886745 on NIH RePORTER |
What this research studies
This research investigates the mechanisms that prevent bladder cancer from responding to immune checkpoint blockade therapy, which is a promising treatment option. By analyzing tumor samples from patients, the study aims to identify specific immune cell types and gene signatures that contribute to resistance against this therapy. The approach includes creating detailed atlases of bladder tumors, blood, and urine at a single-cell level to better understand the immune landscape in bladder cancer. This information could help tailor treatments to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer who are considering or currently undergoing immune checkpoint blockade therapy.
Not a fit: Patients with bladder cancer who are not eligible for immune checkpoint blockade therapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that extend the benefits of immune therapy to more bladder cancer patients.
How similar studies have performed: Other research has shown promise in understanding immune resistance mechanisms in various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Tran, Michelle Alyssa — Icahn School of Medicine at Mount Sinai
- Study coordinator: Tran, Michelle Alyssa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.